Checking up on checkpoint inhibitors

Abstract

In this issue of Blood, Haverkos et al present timely and compelling data revealing both the opportunity and serious hazards incurred with the use of programmed death 1 (PD-1) pathway blockade after allogeneic hematopoietic cell transplant (allo-HCT) in relapsed lymphoma patients.1